AbbVie Inc. Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation
AbbVie Inc. (ABBV) reported Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation of $186.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-21.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rate
us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1 · last filed 2020-02-21
- AbbVie Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2019 was $186.00M, a 113.79% increase from fiscal 2018.
- AbbVie Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2018 was $87.00M, a 37.86% decline from fiscal 2017.
- AbbVie Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2017 was $140.00M, a 47.37% increase from fiscal 2016.
- AbbVie Inc. defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2016 was $95.00M, a 5.56% increase from fiscal 2015.
| Period end | Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation 12 month |
|---|---|
| 2019-12-31 | $186.00M 10-K · filed 2020-02-21 |
| 2018-12-31 | $87.00M 10-K · filed 2019-02-27 |
| 2017-12-31 | $140.00M 10-K · filed 2018-02-16 |
| 2016-12-31 | $95.00M 10-K · filed 2017-02-17 |
| 2015-12-31 | $90.00M 10-K · filed 2016-02-19 |
| 2014-12-31 | -$92.00M 10-K · filed 2015-02-20 |
| 2013-12-31 | -$56.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |